Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16457233 | 0.96 | HTR2C (0.72) | HTR2CDRD2HTR2AHTR2BHTR1A | |
| SCHEMBL5668848 | 0.94 | HTR2C (0.70) | HTR2CDRD2HTR2AHTR2B | |
| SCHEMBL31087548 | 0.94 | HTR2C (0.70) | HTR2CDRD2HTR2AHTR2B | |
| SCHEMBL1065758 | 0.92 | HTR2C (0.77) | HTR2CDRD2HTR2AHTR2BHTR1A | |
| Cyanide SCHEMBL27792102 | 0.87 | HTR2C (0.70) | HTR2CDRD2HTR2AHTR2BHTR1A | |
| SCHEMBL20095988 | 0.85 | HTR2C (0.55) | HTR2CDRD2HTR2AHTR2BKDM1A | |
| SCHEMBL21311601 | 0.85 | HTR2C (0.55) | HTR2CDRD2HTR2AHTR2BKDM1A | |
| SCHEMBL21311688 | 0.85 | HTR2C (0.55) | HTR2CDRD2HTR2AHTR2BKDM1A | |
| SCHEMBL4068122 | 0.85 | HTR2C (0.68) | HTR2CDRD2HTR2AHTR2BHTR1A | |
| SCHEMBL20096265 | 0.84 | HTR2C (0.54) | HTR2CDRD2HTR2AHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028056-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-108699048-A | Oxadiazolamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2018-10-23 | — | — | CN | disclosed |
| EP-2887802-A2 | METHODS OF SOIL PEST CONTROL | Syngenta Participations AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029708-A1 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029710-A2 | METHODS OF SOIL PEST CONTROL | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029707-A1 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029706-A2 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014019609-A1 | METHODS OF PEST CONTROL IN SOYBEAN | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-06 | — | — | WO | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | HTR2C 917/4885DRD2 2533/4885HTR2A 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.